Navigation Links
EntreMed Files New Drug Global Clinical Trial Application For ENMD-2076 With China CFDA
Date:1/13/2014

ROCKVILLE, Md., Jan. 13, 2014 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of diseases, announced today that it has moved to expand its Phase 2 clinical trial for its drug candidate ENMD-2076 in advanced ovarian clear cell carcinoma (OCCC) with the submission of a new drug global clinical trial application with China's Food and Drug Administration (CFDA).  The ongoing Phase 2 trial is currently being conducted at Princess Margaret Cancer Centre in Toronto, along with participation from up to seven additional cancer centers in Canada and the U.S.

(Logo:  http://photos.prnewswire.com/prnh/20010620/ENMDLOGO )

This application is the Company's third new drug global clinical trial application with the CFDA.  The first was announced in January 2013 for triple-negative breast cancer, which is being conducted at the University of Colorado and at Indiana University. The second was announced in June 2013 for the advanced/metastatic soft tissue sarcoma trial, which is being conducted at Princess Margaret Hospital.  More information about the Company's clinical trials can be found at www.clinicaltrials.gov.

Ken K. Ren, Ph.D., EntreMed's Chief Executive Officer, commented, "We are advancing our clinical trials in targeted patient populations in North America, while expanding the trials into China to reach our goal of achieving clinical inflection points more cost-effectively. This North America/China business model is com
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EntreMed Reports First Quarter 2012 Financial Results
2. EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
3. EntreMed Reports Second Quarter 2012 Financial Results
4. Dana-Farber Cancer Institutes Ursula A. Matulonis, MD Article on EntreMeds ENMD-2076 Published in the European Journal of Cancer
5. EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
6. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
7. EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
8. EntreMed To Raise $10.7 Million In Registered Direct Offering
9. EntreMed Reports Fourth Quarter And Year-End 2012 Financial Results And Business Outlook For 2013
10. EntreMed Announces Changes to Board of Directors and CEO Appointment
11. Patent Issued In U.S. For EntreMeds 2ME2 In Rheumatoid Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Company (NASDAQ: STAA ), a leading developer, manufacturer and ... today reported financial results for the second quarter ended July ... Net Sales of $18.7 Million Down 7% from the Prior ... from the Weakening Euro and Yen , ICL Units ... APAC Sales Down 1% Including Korea - Up 16% Excluding ...
(Date:7/29/2015)... 2015 Varian Medical Systems, Inc., (NYSE: VAR ... European subsidiaries, agreed to acquire Claymount, a privately-held, ... for X-ray imaging equipment manufacturers. Varian,s subsidiary in ... in cash for Claymount. The transaction is expected to ... one of the world,s leading suppliers of high voltage ...
(Date:7/29/2015)... (Vanda) (NASDAQ: VNDA ), today announced financial and ... 2015. "We are impressed with U.S. sales ... Polymeropoulos M.D., Vanda,s President and CEO, "further investments in ... set the stage for the next level of growth ... Total net product sales for the second quarter of ...
Breaking Medicine Technology:STAAR Surgical Reports Second Quarter 2015 Results 2STAAR Surgical Reports Second Quarter 2015 Results 3STAAR Surgical Reports Second Quarter 2015 Results 4STAAR Surgical Reports Second Quarter 2015 Results 5STAAR Surgical Reports Second Quarter 2015 Results 6STAAR Surgical Reports Second Quarter 2015 Results 7STAAR Surgical Reports Second Quarter 2015 Results 8STAAR Surgical Reports Second Quarter 2015 Results 9STAAR Surgical Reports Second Quarter 2015 Results 10STAAR Surgical Reports Second Quarter 2015 Results 11STAAR Surgical Reports Second Quarter 2015 Results 12STAAR Surgical Reports Second Quarter 2015 Results 13STAAR Surgical Reports Second Quarter 2015 Results 14STAAR Surgical Reports Second Quarter 2015 Results 15STAAR Surgical Reports Second Quarter 2015 Results 16STAAR Surgical Reports Second Quarter 2015 Results 17STAAR Surgical Reports Second Quarter 2015 Results 18STAAR Surgical Reports Second Quarter 2015 Results 19STAAR Surgical Reports Second Quarter 2015 Results 20STAAR Surgical Reports Second Quarter 2015 Results 21STAAR Surgical Reports Second Quarter 2015 Results 22STAAR Surgical Reports Second Quarter 2015 Results 23STAAR Surgical Reports Second Quarter 2015 Results 24Varian Medical Systems Acquiring Claymount to Expand Imaging Components Portfolio 2Varian Medical Systems Acquiring Claymount to Expand Imaging Components Portfolio 3Varian Medical Systems Acquiring Claymount to Expand Imaging Components Portfolio 4Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 2Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 3Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 4Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 5Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 6Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 7Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 8Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 9Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 10
... LONDON, June 24 Morria Biopharmaceuticals Plc, a,biopharmaceutical ... today announced that it has initiated a Phase ... formulation, in 105 patients,suffering from allergic rhinitis (AR). ... as the steroid,comparator arm. The study is expected ...
... Study on Track to Complete Accrual in Fourth ... Genta,Incorporated (OTC Bulletin Board: GNTA) announced the ... 3 trial of Genasense(R) (oblimersen,sodium) Injection, the Company,s ... data were presented at a satellite investigator,s,meeting held ...
Cached Medicine Technology:Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis 2Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma 2Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma 3Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma 4Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma 5
(Date:7/29/2015)... Los Angeles, CA (PRWEB) , ... July 29, 2015 , ... According to an ... published by the National Institutes of Health shows exactly what a person needs to do ... sex, height, and weight, the app will give informed estimates as to the number of ...
(Date:7/29/2015)... ... July 29, 2015 , ... In an effort to ... problems of substance abuse that face today’s society, A Forever Recovery invited members ... their rehabilitation center. The facility, located in Southwest Michigan hosted a tour of ...
(Date:7/29/2015)... ... July 29, 2015 , ... This past week, ... surrogacy journey from a treasured member of the CARE extended family. , By ... to help intended parents across the globe gain a newfound perspective on surrogacy in ...
(Date:7/29/2015)... ... July 29, 2015 , ... Abt Associates has ... U.S. Health division. In her position, Ramkeesoon will help build and expand ... Abt, Ramkeesoon spent close to a decade at ICF International, most recently as ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... health inequities. Since 2012, Massachusetts law has provided legal protections against discrimination on ... the law does not protect against discrimination based on gender identity in places ...
Breaking Medicine News(10 mins):Health News:New NIH Body Weight Planner Illustrates the Need for Reduced Caloric Intake When Trying to Lose Weight, Says Beverly Hills Physicians 2Health News:MADD Victim Services Specialist Visits A Forever Recovery Rehabilitation Facility 2Health News:Heartfelt Interview Shows Extraordinary Impact of CARE Surrogacy Center Mexico 2Health News:Heartfelt Interview Shows Extraordinary Impact of CARE Surrogacy Center Mexico 3Health News:Selena Ramkeesoon Joins Abt Associates as Vice President for Strategic Communications 2Health News:Fenway Health Researcher: Legal Protections in Public Settings are a Critical Public Health Issue for Transgender and Gender-Nonconforming People 2Health News:Fenway Health Researcher: Legal Protections in Public Settings are a Critical Public Health Issue for Transgender and Gender-Nonconforming People 3
... previous poll, Democratic contender,still enjoys broad support, ... waning days of the,2008 Presidential Campaign, healthcare providers ... McCain (R-Ariz.) by a sizable margin,according to an ... )., (Photo: http://www.newscom.com/cgi-bin/prnh/20081103/NY43443 ), ...
... 3 /PRNewswire-FirstCall/ - Predictive medicine company,PreMD Inc. (TSX: PMD; ... Stock Exchange ("TSX") that it is reviewing the eligibility ... TSX., The Company is being reviewed under the ... to comply with all requirements for continued,listing. If the ...
... tumor sites were cervix, head and neck, government study ... estimated 25,000 cases of cancers associated with human papillomavirus ... Columbia between 1998 and 2003, U.S. officials reported Monday. ... more than 100 different types, more than 30 of ...
... less safe than Cox-1 drugs, like naproxen, study says ... risk of heart attack that comes with the use ... is directly related to the specific pain-causing molecule they ... a significant correlation between the degree of inhibition in ...
... ongoing efforts to educate the public about HIV, a ... Harvard University and Children,s Hospital Boston has found that ... about spreading HIV in the home. , The qualitative ... including minor children, in families with an HIV-infected parent ...
... Health Enhancement Systems Studies (CHESS) has been awarded a ... division of the National Institutes of Health (NIH), to ... research. , The five-year, $8.6 million grant for the ... II) will investigate problems associated with cancer communication in ...
Cached Medicine News:Health News:Election-Eve MedPage Today(R) Poll Gives Obama Double-Digit Lead Among Clinicians 2Health News:Election-Eve MedPage Today(R) Poll Gives Obama Double-Digit Lead Among Clinicians 3Health News:Listing Review initiated by the Toronto Stock Exchange 2Health News:U.S. Reported 25,000 Cases of HPV-Related Cancers Annually 2Health News:Study Sheds Light on Painkillers' Heart Risk 2Health News:Study Sheds Light on Painkillers' Heart Risk 3Health News:Study finds fears of HIV transmission in families with infected parent 2Health News:Center for Health Enhancement Systems Studies awarded $8.6 million NIH grant 2
... provides both pressure and flow calculations ... in a combined screen format utilizing ... Volcano's unique Doppler FloWire. Physiologic measurements ... to assess ambiguous or intermediate lesions, ...
... D-Series Plus from BERCHTOLD offers you a complete ... returning 98% of the bulb's original illumination to ... radiant energy., ,The light field is clear and ... and a neutral white color temperature of 4500 ...
... Convert any EMG/EP or EEG ... with these easy-to-install adapters. Available in ... Department at 1-800-245-3001 or 509-735-6481 for ... other manufacturers equipment. Sold individually. Adhesive ...
... elastic fabric, these head cap systems are ... begin testing. Each Electro-Cap System features pure ... 10-20 System. When you place your order, ... with your head cap system and whether ...
Medicine Products: